PropertyValue
?:abstract
  • Regeneron Pharmaceuticals has offered a first glimpse at data from closely watched studies of REGN-COV2, its antibody therapy for Although not a home run, the results do provide insight into where antibodies might fit into the treatment landscape for the disease Regeneron’s drug is a cocktail of two antibodies that bind to the spike protein in different spots of the coronavirus that causes COVID-19 The virus uses the spike to latch onto human cells before dumping its genetic payload inside Clinical trials of the treatment, which began in June, have enrolled some 2,000 people The first data came from 275 people whose infection had not yet put them in the hospital Out of that group, the drug appeared to be most effective in people whose immune systems were not yet kicking in to produce antibodies to clear the virus The question now is whether that is enough for the [ ]
is ?:annotates of
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Early peek at Regeneron drug
?:type
?:who_covidence_id
  • #841849
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/opxyvfd3>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/opxyvfd3>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all